department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Veozah · pharmadog

pharmadog
drugs
Veozah

drug

patient view →

fezolinetant

Marketedupdated 2mo ago

by Astellas Pharma US Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Veozah

generic

fezolinetant

indication

Vasomotor Symptoms of Menopause (Hot Flashes)

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 49m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

May 12, 2028

~1.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Mar 28, 2034method-of-use (U-3622)US 10836768
Mar 28, 2034compositionUS 9422299
Mar 28, 2034method-of-use (U-3622)US 9987274
Apr 4, 2031compositionUS 88717614.7y

FDA exclusivities (1)

May 12, 2028NCENew Chemical Entity (5y)1.8y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying fezolinetant

phase2FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapyrecruitingn=92
phase3A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopausecompletedn=277
phase3A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapyactive not recruitingn=984
phase2A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopausecompletedn=150
phase2Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapyrecruitingn=60
—A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During Menopauseactive not recruitingn=105
—A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweatsactive not recruitingn=999
phase3A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopausecompletedn=410

more trials →